课题基金 / 基金详情

Repositioning of Clinically Approved Drugs toward the Prevention and Risk Evaluation of Early Cataract Progression

Repositioning of Clinically Approved Drugs toward the Prevention and Risk Evaluation of Early Cataract Progression
重新定位临床批准药物以预防早期白内障进展并进行风险评估
批准号:
10164795
负责人:
VINCENT M MONNIER
金额:
$65.86万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2024-05-31

项目摘要

项目成果

VINCENT M MONNIER的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 老年性白内障是一种普遍的、进展缓慢的隐匿性致盲疾病,影响20 一百万65岁以上的美国人。然而,目前尚不清楚为什么白内障进展更快。 一些人与其他人相比,这些人似乎受到了保护,在高龄时没有白内障。 晶状体混浊不同个体进展率的存在意味着 是否存在保护性因素以及有害因素目前还知之甚少。我们 假设在今天的临床批准的药物中,有候选药物 具有抗白内障的特性,因此可以这样开发,而其他可能 有患者和医学界不知道的促进白内障的特性。 为了验证这一假设,我们建议结合两种创新和互补的方法, 即,在临床批准的药物中同时识别 潜在的抗白内障和促白内障化合物,其实验方法针对 同时确定在体外防止或恶化的药物会产生氧化应激和 晶状体晶体蛋白不稳定。从这种双重方法中产生的候选药物将在 老年性白内障的小鼠模型。 使用由计算药物专家团队组成的多PI策略 重新定位,以及高通量筛选小分子、动物的专家团队 老年性白内障模型,在氧化应激和蛋白质聚集方面,我们提出了四种 四年期间的重点目标和可实现的目标:目标1:开发新的数据驱动型 识别重新定位的抗白内障药物和促进白内障风险的计算算法 来自FDA批准的所有药物的药物。目标2:FDA批准的2650种临床药物的测试 研究其对蛋白质的功效或有害特性的微源谱库 氧化代谢损伤等三种体外应激模型体系的聚集/变性 对γ和β晶体蛋白、紫外线照射和全晶状体体外孵育应激。目标3: 在计算机上测试从上面出现的排名靠前的候选药物,并进行实验搜索 两种小鼠模型对白内障进展的潜在治疗或有害作用 白内障,即LEGSKO/GCLM(双基因敲除)DKO小鼠和α晶体蛋白R120G 突变的敲入鼠。目标4:开发一个全面的知识库,并将所有数据 通过交互式Web应用程序公开提供。成功地实施了这一创新的 该计划预计将在白内障领域产生变革性的影响,潜在地 将已知药物重新定位为早期预防白内障和白内障进展风险 评估。
英文摘要
ABSTRACT Age-related cataract is a universal, slowly progressive, insidious blinding disease that affects 20 million Americans above the age of 65 years. Yet, it is unclear why cataract progresses faster in some vs other individuals who are seemingly protected and cataract free at an advanced age. The existence of differential progression rates of lens opacification among individuals implies the existence of protective as well as deleterious factors that are as yet poorly understood. We hypothesize that there are, among today’s clinically approved drugs, candidate drugs that have anti-cataract properties, and therefore could be developed as such, while others may have cataract promoting properties unbeknownst to patients and the medical community. To test this hypothesis, we propose to combine two innovative and complementary approaches, i.e. a computational approach to simultaneously identify, among clinically approved drugs, potentially anti- and pro-cataractogenic compounds, with an experimental approach geared at simultaneously identifying drugs that prevent or worsen in vitro generated oxidative stress and lens crystallin destabilization. Candidate drugs emerging from this dual approach will be tested in mouse models of age-related cataract. Using a multi-PI strategy consisting of a team of experts in computational drug repositioning, and a team of experts in high throughput screening of small molecules, animal models of age-related cataract, in oxidative stress and protein aggregation, we propose four focused and achievable goals over a four year period: Aim 1: Development of novel data-driven computational algorithms to identify repositioned anti-cataract drugs and cataract risk promoting drugs from all FDA-approved drugs. Aim 2: Testing of 2650 FDA approved clinical drugs from the Microsource Spectrum library for their efficacy or deleterious properties on protein aggregation/denaturation in three in vitro stress model systems, i.e. oxidative metabolic damage to gamma and beta crystallins, UV irradiation and whole lens in vitro incubation stress. Aim 3: Test the top candidate drugs emerging from the above in silico and experimental search for their potential therapeutic or deleterious activity on cataract progression in two mouse models of cataract, i.e. the LEGSKO/Gclm (Double knockout) DKO mouse and the alphaB crystallin R120G mutant knock-in mouse. Aim 4: Develop a comprehensive knowledge base and make all the data publicly available via interactive web application. The successful execution of this innovative program is expected to have a transformative impact in the cataract field by potentially repositioning known drugs toward both early cataract prevention as well cataract progression risk assessment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
10th International Symposium on the Maillard Reaction
  • 批准号:
    7751127
  • 项目类别:
  • 资助金额:
    $1.75万
  • 财政年份:
    2009
  • 负责人:
    VINCENT M MONNIER
  • 依托单位:
9th International Symposium on the Maillard Reaction
  • 批准号:
    7407292
  • 项目类别:
  • 资助金额:
    $1.65万
  • 财政年份:
    2007
  • 负责人:
    VINCENT M MONNIER
  • 依托单位:
Core--Animal facility
  • 批准号:
    6659261
  • 项目类别:
  • 资助金额:
    $9.46万
  • 财政年份:
    2002
  • 负责人:
    VINCENT M MONNIER
  • 依托单位:
Oxidant stress & ascorbic acid processing in diabetes
  • 批准号:
    6659258
  • 项目类别:
  • 资助金额:
    $9.46万
  • 财政年份:
    2002
  • 负责人:
    VINCENT M MONNIER
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: